10-QPeriod: Q2 FY2021

STRYKER CORP Quarterly Report for Q2 Ended Jun 30, 2021

Filed July 28, 2021For Securities:SYK

Summary

Stryker Corporation reported a strong second quarter for 2021, demonstrating a significant recovery from the COVID-19 impacted prior year. Net sales surged by 55.4% year-over-year, driven by robust growth across all segments, particularly Orthopaedics, which saw an 82.3% increase. This recovery was fueled by the resumption of elective procedures and higher unit volumes, with international markets also showing strong performance. The company's profitability significantly improved, with net earnings reaching $592 million, a substantial rebound from a net loss in the prior year period. This financial strength is underpinned by improved gross profit margins and effective cost management, as highlighted by the increase in adjusted operating income margin. The company's strategic focus on innovation and acquisitions continues, notably the integration of Wright Medical. While facing ongoing recall-related charges and potential impacts from China's volume-based procurement programs, Stryker's financial position remains solid. The balance sheet shows healthy current assets and a manageable debt structure. Management's confidence is reflected in their continued investment in R&D and their stated belief in the ongoing recovery of elective procedures.

Financial Highlights

51 data points
Beta

Revenue

$4.29B

64.6% Gross Margin

Net Income

$592.00M

13.8% Net Margin

EPS (Diluted)

$1.55

Total Assets

$33.70B

Cash & Equivalents

$2.24B

Free Cash Flow

$772.00M

Financial Statements
Beta
Revenue$4.29B
Cost of Revenue$1.52B
Gross Profit$2.77B
R&D Expenses$310.00M
SG&A Expenses$1.50B
Operating Expenses$2.04B
Operating Income$732.00M
Net Income$592.00M
EPS (Basic)$1.57
EPS (Diluted)$1.55
Shares Outstanding (Basic)376.90M
Shares Outstanding (Diluted)382.30M

Key Highlights

  • 1Net sales for the second quarter of 2021 increased by a substantial 55.4% to $4.3 billion, compared to $2.76 billion in the prior year period, indicating a strong recovery.
  • 2Operating income rebounded significantly, reaching $732 million in Q2 2021, a dramatic improvement from an operating loss of $20 million in Q2 2020.
  • 3Net earnings for the quarter were $592 million, or $1.55 per diluted share, a significant turnaround from a net loss of $83 million, or ($0.22) per diluted share, in the same period last year.
  • 4The Orthopaedics segment experienced exceptional growth, with net sales increasing by 82.3% to $1.63 billion, driven by strong demand for knees, hips, and trauma/extremities products.
  • 5Gross profit margin improved to 64.6% in Q2 2021 from 56.0% in Q2 2020, reflecting improved operational leverage and favorable product mix.
  • 6The company incurred recall charges of $76 million in the quarter, primarily related to hip stems, which impacted profitability but were managed within the context of overall strong performance.
  • 7Stryker continued its debt management, repaying $750 million of senior unsecured notes and a $400 million term loan during the first half of 2021, while maintaining a strong liquidity position.

Frequently Asked Questions

The substantial 55.4% increase in net sales to $4.3 billion was primarily driven by the recovery in elective medical procedures that were significantly impacted by the COVID-19 pandemic in the prior year. Higher unit volumes across most product categories, particularly in Orthopaedics and Neurotechnology & Spine segments, and strong performance in international markets also contributed significantly to the sales growth.

Profitability has dramatically improved. Operating income surged to $732 million in Q2 2021 from an operating loss of $20 million in Q2 2020. Net earnings were $592 million, a substantial rebound from a net loss of $83 million in the prior year. This improvement is also reflected in the gross profit margin, which increased to 64.6% from 56.0%, and the operating income margin, which rose to 17.0% from -0.7%.

The acquisition of Wright Medical, completed in late 2020, contributed to the growth in the Orthopaedics segment, particularly in Trauma and Extremities. While the integration of Wright Medical is ongoing and has contributed to increased amortization of intangible assets, it is a key part of Stryker's strategy to expand its offerings in extremities and biologics, supporting the overall segment growth.

Investors should be aware of the recall charges of $76 million incurred in Q2 2021, primarily related to past hip stem recalls. Additionally, the company is monitoring the impact of China's volume-based procurement (VBP) programs, which could negatively affect future commercial operations in that region and potentially lead to asset impairments. However, the company has a robust balance sheet and strong cash flow generation to manage these risks.